Editing Tuberculosis (section)

=== Latent TB ===

Latent TB is treated with either [[isoniazid]] or [[rifampin]] alone, or a combination of isoniazid with either rifampicin or rifapentine.<ref name="WHO_Latent_2018">{{cite book | publisher=[[World Health Organization]] (WHO) | title=Latent tuberculosis infection | year=2018 | page=23 | isbn=978-92-4-155023-9 | url=http://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf;jsessionid=E08401544A59BE3F84C645C9A9A7B0E5?sequence=1 | access-date=25 July 2018 | archive-date=2 June 2021 | archive-url=https://web.archive.org/web/20210602215123/http://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf;jsessionid=E08401544A59BE3F84C645C9A9A7B0E5?sequence=1 | url-status=live }}</ref><ref>{{cite journal | vauthors = Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, Yelk Woodruff R, Allen L, LoBue P, Vernon A | title = Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection | journal = MMWR. Morbidity and Mortality Weekly Report | volume = 67 | issue = 25 | pages = 723–726 | date = June 2018 | pmid = 29953429 | pmc = 6023184 | doi = 10.15585/mmwr.mm6725a5 }}</ref><ref name="Sterling-2020">{{cite journal | vauthors = Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R | title = Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 | language = en-us | journal = MMWR. Recommendations and Reports | volume = 69 | issue = 1 | pages = 1–11 | date = February 2020 | pmid = 32053584 | pmc = 7041302 | doi = 10.15585/mmwr.rr6901a1 }}</ref>

The treatment takes three to nine months depending on the medications used.<ref>{{cite web |year=2011 |title=Core Curriculum on Tuberculosis: What the Clinician Should Know |url=https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf |url-status=live |archive-url=https://web.archive.org/web/20120519141115/http://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf |archive-date=19 May 2012 |publisher=[[Centers for Disease Control and Prevention]] (CDC), Division of Tuberculosis Elimination |page=24 |edition=5th}}</ref><ref name="WHO_Latent_2018" /><ref>{{cite journal | vauthors = Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS | title = Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis | journal = American Journal of Preventive Medicine | volume = 55 | issue = 2 | pages = 244–252 | date = August 2018 | pmid = 29910114 | pmc = 6097523 | doi = 10.1016/j.amepre.2018.04.030 }}</ref><ref name="Sterling-2020" /> People with latent infections are treated to prevent them from progressing to active TB disease later in life.<ref>{{cite journal | vauthors = Menzies D, Al Jahdali H, Al Otaibi B | title = Recent developments in treatment of latent tuberculosis infection | journal = The Indian Journal of Medical Research | volume = 133 | issue = 3 | pages = 257–66 | date = March 2011 | pmid = 21441678 | pmc = 3103149 }}</ref>

Education or counselling may improve the latent tuberculosis treatment completion rates.<ref>{{cite journal | vauthors = M'imunya JM, Kredo T, Volmink J | title = Patient education and counselling for promoting adherence to treatment for tuberculosis | journal = The Cochrane Database of Systematic Reviews | issue = 5 | pages = CD006591 | date = May 2012 | volume = 2012 | pmid = 22592714 | pmc = 6532681 | doi = 10.1002/14651858.CD006591.pub2  | collaboration = Cochrane Infectious Diseases Group }}</ref>